Objective: To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and esophagogastric juncti...Objective: To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and esophagogastric junction (EGJ) adenocarcinoma in China. Methods: The patients were treated with paclitaxel 150 mg/m2 on dl; fractionated cisplatin 15 mg/m2 and continuous infusion 5-FU 600 mg/(mLd) intravenously on d 1-d5 of a 21-d cycle until disease progression or unacceptable toxicities. Results: Seventy-five patients have been enrolled, among which, 41 received PCF regimen as the first-line therapy (group A) and 34 received the regimen as the second-line therapy (group B) with the median age of 59 years old and Karnofsky performance status (KPS) score 〉80. Toxicities were analyzed in all 75 patients. Seventy-one patients were evaluable for efficacy. The median overall survival (mOS) was 12.0 months (95% CI: 7.9-16.2 months) in group A and 7.3 months (95% CI: 4.3-10.3 months) in group B, respectively. The median progression-free survival (mPFS) was 5.7 months (95% CI: 4.1-7.2 months) and 5.0 months (95% CI: 3.1-6.9 months), respectively. The response rate (CR^PR) was 40% (16/40; 95% CI: 24.9-56.7%) in group A and 22.6% (7/31; 95% CI: 9.6-41.1%) in group B. Major grade 3 or 4 adverse events include neutropenia (41.3 %), febrile neutropenia (9.3 %), nausea/anorexia (10.7%), and vomiting (5.3 %). There was no treatment-related death. Conclusions: The combination chemotherapy with PCF is active and tolerable as first-line and second- line therapy in Chinese patients with advanced gastric and EGJ adenocarcinoma. The response and survival of PCF are same as those of DCF, but the tolerance is much better.展开更多
目的:回顾性分析中日两家医院胃癌患者临床资料的发病特点及手术治疗方面的异同,为提高胃癌的诊治水平提供临床参考。方法:收集2016-04~2016-09山西省肿瘤医院(CXCIL)和日本埼玉医科大学国际医疗中心(SMIC)收治的胃癌患者的临床资料,对...目的:回顾性分析中日两家医院胃癌患者临床资料的发病特点及手术治疗方面的异同,为提高胃癌的诊治水平提供临床参考。方法:收集2016-04~2016-09山西省肿瘤医院(CXCIL)和日本埼玉医科大学国际医疗中心(SMIC)收治的胃癌患者的临床资料,对其临床特征,手术情况及术后管理进行比较分析。结果:两组患者的性别无差异,而在年龄、肿瘤发生部位、临床分期上有显著差异。与日本患者相比,中国患者的平均发病年龄较年轻(58.5±10.7a vs 70.4±9.5a,P<0.001),胃上1/3部癌(包括食管胃结合部癌)发病比率较高(38.4%vs 12.4%,P<0.001),早期癌尤其是Ⅰ期胃癌检出率较低(19.9%vs 43.8%,P<0.001)。针对胃上1/3部癌病例,我院采用全胃切除术,而日方多采用部分胃切除术(100%vs 60%)。对比根治手术病例,我院手术时间较短(177.0±41.7 min vs 256.8±69.2 min,P<0.001),但是术中出血量偏多(148.0±118.6 mL vs 124.1±192.1 mL,P<0.001),淋巴结清扫的数目少(25.6±10.9 vs36.9±15.6,P<0.001)。中方患者术后开始进食时间偏晚(10.4±6.7d vs 3.4±2.1d,P<0.001),术后住院时间更长(18.2±13.9d vs 10.1±5.1d,P<0.001),术后并发症发生几率更高(11.8%vs 23.8%,P=0.015)。两家医院采用腹腔镜手术的比率大致相同(63.1%vs 51,P=0.057)。结论:两家医院收治患者的胃癌发病特点不同,双方在手术方式的选择上存在差异,日本医院在术后快速康复的措施应用可提供参考。展开更多
文摘Objective: To evaluate the efficacy and toxicity of the combination regimen of paclitaxel, cisplatin and 5-FU (PCF) as first-line or second-line therapy in patients with advanced gastric and esophagogastric junction (EGJ) adenocarcinoma in China. Methods: The patients were treated with paclitaxel 150 mg/m2 on dl; fractionated cisplatin 15 mg/m2 and continuous infusion 5-FU 600 mg/(mLd) intravenously on d 1-d5 of a 21-d cycle until disease progression or unacceptable toxicities. Results: Seventy-five patients have been enrolled, among which, 41 received PCF regimen as the first-line therapy (group A) and 34 received the regimen as the second-line therapy (group B) with the median age of 59 years old and Karnofsky performance status (KPS) score 〉80. Toxicities were analyzed in all 75 patients. Seventy-one patients were evaluable for efficacy. The median overall survival (mOS) was 12.0 months (95% CI: 7.9-16.2 months) in group A and 7.3 months (95% CI: 4.3-10.3 months) in group B, respectively. The median progression-free survival (mPFS) was 5.7 months (95% CI: 4.1-7.2 months) and 5.0 months (95% CI: 3.1-6.9 months), respectively. The response rate (CR^PR) was 40% (16/40; 95% CI: 24.9-56.7%) in group A and 22.6% (7/31; 95% CI: 9.6-41.1%) in group B. Major grade 3 or 4 adverse events include neutropenia (41.3 %), febrile neutropenia (9.3 %), nausea/anorexia (10.7%), and vomiting (5.3 %). There was no treatment-related death. Conclusions: The combination chemotherapy with PCF is active and tolerable as first-line and second- line therapy in Chinese patients with advanced gastric and EGJ adenocarcinoma. The response and survival of PCF are same as those of DCF, but the tolerance is much better.
文摘目的:回顾性分析中日两家医院胃癌患者临床资料的发病特点及手术治疗方面的异同,为提高胃癌的诊治水平提供临床参考。方法:收集2016-04~2016-09山西省肿瘤医院(CXCIL)和日本埼玉医科大学国际医疗中心(SMIC)收治的胃癌患者的临床资料,对其临床特征,手术情况及术后管理进行比较分析。结果:两组患者的性别无差异,而在年龄、肿瘤发生部位、临床分期上有显著差异。与日本患者相比,中国患者的平均发病年龄较年轻(58.5±10.7a vs 70.4±9.5a,P<0.001),胃上1/3部癌(包括食管胃结合部癌)发病比率较高(38.4%vs 12.4%,P<0.001),早期癌尤其是Ⅰ期胃癌检出率较低(19.9%vs 43.8%,P<0.001)。针对胃上1/3部癌病例,我院采用全胃切除术,而日方多采用部分胃切除术(100%vs 60%)。对比根治手术病例,我院手术时间较短(177.0±41.7 min vs 256.8±69.2 min,P<0.001),但是术中出血量偏多(148.0±118.6 mL vs 124.1±192.1 mL,P<0.001),淋巴结清扫的数目少(25.6±10.9 vs36.9±15.6,P<0.001)。中方患者术后开始进食时间偏晚(10.4±6.7d vs 3.4±2.1d,P<0.001),术后住院时间更长(18.2±13.9d vs 10.1±5.1d,P<0.001),术后并发症发生几率更高(11.8%vs 23.8%,P=0.015)。两家医院采用腹腔镜手术的比率大致相同(63.1%vs 51,P=0.057)。结论:两家医院收治患者的胃癌发病特点不同,双方在手术方式的选择上存在差异,日本医院在术后快速康复的措施应用可提供参考。